Ashland announced on April 13, 2026 the launch of Eternight biofunctional, a new Iris roots extract powered by PSR technology that targets mitochondrial health for nighttime skin care. The ingredient is built around humanin, a mitochondrial‑derived peptide linked to longevity in centenarians, and is positioned as a mitorestoration agent that supports cellular repair during the night.
Eternight biofunctional is formulated for use in night creams, serums, and longevity‑focused skincare routines. The product leverages Ashland’s proprietary PSR (Plant Small RNA) technology, a natural‑derived extractive aqueous ionic solution that enriches water‑soluble phytocompounds and small RNAs, which are epigenetic regulators involved in plant adaptation to stress. The Iris pallida rhizomes are cultivated in France under regenerative agriculture practices that emphasize soil health and biodiversity.
The launch is part of Ashland’s broader strategy to expand its biofunctional portfolio in consumer‑facing specialty ingredients, aiming to capture demand for science‑backed, longevity‑focused beauty products. Ashland’s existing Transformed Vegetable Oils and GLP‑1 platforms complement the new ingredient, positioning the company to differentiate in a crowded beauty ingredient space and potentially drive future growth in the high‑margin consumer‑care market.
Management highlighted the significance of the new ingredient. “With eternight™, we are redefining how skin longevity can be approached in cosmetics,” said Isabelle Imbert, director of research and development, biofunctionals. “Eternight™ brings together science and longevity storytelling in a way that truly resonates with today's consumers.” Justine Cotton, global marketing manager, biofunctionals, added, “From the underground secret of the iris flower to the cutting edge science of mitobiology™ and Blue Zone longevity, eternight™ offers brands a powerful, credible narrative rooted in both nature and advanced biology.”
Ashland’s Q1 2026 earnings, released earlier in the year, showed a 5% decline in overall sales and an 8% drop in Personal Care sales compared with the prior year, partly due to the Avoca divestiture. Despite the revenue miss of $386 million versus an estimate of $401.42 million, the company beat earnings expectations with an EPS of $0.26 against an estimate of $0.23, reflecting disciplined cost management and margin resilience. The market reaction to the earnings release was muted, with the stock declining 1.4% over the past week and 2.1% over the past two weeks.
While no specific market reaction to the Eternight launch has been reported, the product’s positioning in the growing longevity‑focused beauty segment could open a new premium revenue stream for Ashland. The ingredient’s focus on mitochondrial health and the use of PSR technology align with consumer demand for clean, science‑backed ingredients, potentially strengthening Ashland’s competitive position in the specialty ingredient market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.